Clinical trials: Plaque Psoriasis.
Psoriasis
A Intra-individual Comparison to Investigate the Efficacy and the Safety of LAS41004 Formulation in Mild to Moderate Psoriasis
Proof-of concept study to competitively investigate antipsoriatic efficacy and safety of a LAS41004 formulation vs active control No formal study hypothesis, but descriptive evaluation (PoC).
- Trial name
- Left/Right (NCT02180464)
- Testing
- LAS41004, control
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Almirall, S.A.
Plaque Psoriasis
Study to Evaluate the Efficacy of Enbrel as a Biological Treatment in Moderate to Severe Plaque Psoriasis Patients
This study is to evaluate available local data in Iraqi patients with moderate to severe psoriasis on Enbrel treatment with regards to efficacy, treatment regimen adherence and patient characterization (i.e.
- Trial name
- NCT04398732
- Testing
- Enbrel
- Where
- Iraq
- Volunteers
- 486 people
- Sponsor
- Pfizer
Psoriasis
A Study to Evaluate the Benefit and Safety of GSK2982772 in Moderate to Severe Psoriasis Participants
Plaque psoriasis is a chronic relapsing inflammatory skin disease that is characterized by keratinocyte hyper-proliferation and epidermal hyperplasia.
- Trial name
- NCT04316585
- Testing
- GSK2982772
- Where
- 9 sites in Canada, Poland
- Volunteers
- 29 people
- Sponsor
- GlaxoSmithKline
Moderate to Severe Plaque Psoriasis
An Observational Study to Evaluate Patient-Reported Experiences of Living With Moderate-to-Severe Plaque Psoriasis
The purpose of the study is to develop a database containing patient-reported information that may be used to understand and to increase awareness of the impact that moderate-to-severe plaque psoriasis can have on both daily life…
- Trial name
- NCT01555606
- Testing
- No intervention
- Where
- 9 sites in United States
- Volunteers
- 108 people
- Sponsor
- Janssen Biotech, Inc.
Atopic Dermatitis, Plaque Psoriasis
A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis.
The purpose of this clinical trial is to learn about the safety, how well the study medicine works, extent to which side effects can be tolerated, and how the study medicine is changed and eliminated from your body after you…
- Trial name
- NCT05375955
- Testing
- PF-07038124 ointment 0.01%, Vehicle ointment, PF-07038124 ointment 0.03%
- Where
- 39 sites in United States, Canada and 2 more
- Volunteers
- 263 people
- Sponsor
- Pfizer
Psoriasis
Study of MEDI-507 Administered by Intravenous Infusion to Adults With Plaque Psoriasis
The primary objective of this study is to compare disease activity, as measured by PASI score, of two MEDI-507 dose levels (0.012 and 0.04 mg/kg) versus placebo administered by intravenous infusion every 2 weeks for a total of 8…
- Trial name
- NCT00192452
- Testing
- MEDI-507
- Where
- 3 sites in United States
- Volunteers
- 120 people
- Sponsor
- MedImmune LLC
Psoriasis
Study to Evaluate the Pharmacokinetics and the Safety of M518101 in Plaque Psoriasis Patients
This study is to evaluate the pharmacokinetics and safety of M518101 in male and female plaque psoriasis patients.
- Trial name
- NCT01844973
- Testing
- M518101, Vehicle
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Maruho North America Inc.
Plaque Psoriasis
Pharmacokinetic, Efficacy, Safety, and Immunogenicity of AVT02 With Moderate to Severe Chronic Plaque Psoriasis
Pharmacokinetic, Efficacy, Safety, and Immunogenicity Between Patients with Moderate to Severe Chronic Plaque Psoriasis Receiving Humira® and Patients with Moderate to Severe Chronic Plaque Psoriasis
- Trial name
- NCT04453137
- Testing
- Adalimumab originator, Adalimumab biosimilar
- Where
- 25 sites in Georgia, Iceland and 3 more
- Volunteers
- 567 people
- Sponsor
- Alvotech Swiss AG
Psoriasis
Efficacy and Safety Study of NP000888 in Subjects With Plaque and Nail Psoriasis
This study is to evaluate the efficacy and safety of topical application of NP000888 ointment compared to vehicle in plaque and fingernail psoriasis subjects. Duration of administration: 24 weeks
- Trial name
- NCT02995473
- Testing
- NP000888, Vehicle
- Where
- 10 sites in Taiwan
- Volunteers
- 61 people
- Sponsor
- Galderma R&D
Psoriasis
A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)
The purpose of this study is to evaluate the long-term safety and maintenance of efficacy of mirikizumab in participants with moderate-to-severe plaque psoriasis.
- Trial name
- NCT03556202
- Testing
- Mirikizumab
- Where
- 229 sites in United States, Argentina and 17 more
- Volunteers
- 1,936 people
- Sponsor
- Eli Lilly and Company
Psoriasis
Study to Investigate Dose-related Efficacy of LAS41004 in the Treatment of Psoriasis
The aim of the study is to intra-individually compare the dose-related efficacy of LAS41004 in a Psoriasis Plaque Test (PPT)
- Trial name
- NCT01119339
- Testing
- LAS 41004, LAS 41004 dosage 6, Reference
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Almirall, S.A.
Psoriasis
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
The main objective of this study is to evaluate the long-term safety of CP-690,550 in patients being treated for moderate to severe chronic plaque psoriasis.
- Trial name
- NCT01163253
- Testing
- CP-690,550
- Where
- 323 sites in United States, Argentina and 34 more
- Volunteers
- 2,867 people
- Sponsor
- Pfizer
Moderate to Severe Chronic Plaque-type Psoriasis
Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque Psoriasis
The purpose of this study is to assess secukinumab high dose (every 2 weeks) vs standard dose (every 4 weeks) in heavy body weight subjects with moderate to severe plaque psoriasis.
- Trial name
- NCT03504852
- Testing
- secukinumab 150 mg
- Where
- 67 sites in United States, Canada and 5 more
- Volunteers
- 331 people
- Sponsor
- Novartis Pharmaceuticals
Plaque Psoriasis
A Study of DLX105-DMP in Subjects With Plaque Psoriasis
A Pilot, Open-Label Study in Subjects with Mild-to-Moderate Plaque Psoriasis to Investigate the Safety, Tolerability, and Preliminary Efficacy of a Four-Week Multidose Regimen of DLX105-DMP Administered to a Target Lesion
- Trial name
- NCT04203433
- Testing
- DLX105-DMP
- Where
- 4 sites in United States
- Volunteers
- 10 people
- Sponsor
- DelArrivo, Inc.
Psoriasis
Study to Assess the Change in Disease State When Subcutaneous Risankizumab Injection is Given to Adult Participants With Psoriasis in Taiwan
Psoriasis (PsO) is a chronic, disease characterized by marked inflammation of the skin that results in thick, red, scaly plaques and is associated with high burden of illness that results in a negative impact on long-term health…
- Trial name
- NCT04818385
- Where
- 8 sites in Taiwan
- Volunteers
- 240 people
- Sponsor
- AbbVie
Psoriasis Vulgaris
An Exploratory Trial Investigating the Neurogenic Component in Psoriasis Vulgaris by Use of Botulinum Toxin A
The purpose of this study is to evaluate the anti-psoriatic effect of injected Botulinum toxin type A compared to that of injected vehicle.
- Trial name
- NCT02577185
- Testing
- Botulinum Toxin Type A, Sodium chloride 9 mg/ml
- Where
- 2 sites in Denmark
- Volunteers
- 10 people
- Sponsor
- LEO Pharma
Psoriasis Vulgaris
An Exploratory Psoriasis Plaque Test Study With Different Dose Combinations of Calcipotriol Plus Betamethasone Dipropionate in the Daivobet® Gel Vehicle in Psoriasis Vulgaris
The purpose of this study is to evaluate the antipsoriatic effect of 5 different combinations of calcipotriol plus betamethasone dipropionate in Daivobet® gel vehicle in compared to Daivobet® gel in order to explore/find other…
- Trial name
- NCT01837576
- Testing
- Calcipotriol plus BDP gel in different doses
- Where
- France
- Volunteers
- 24 people
- Sponsor
- LEO Pharma
Psoriasis Chronic
Quality of Life in Adalimumab Treated Psoriasis Patients Failing Other Biologic Disease Modifying Anti-rheumatic Drugs
The aim of this post-marketing observational study (PMOS) was to obtain further data on long-term safety, efficacy, and quality of life outcomes for adalimumab in routine clinical use in participants with moderate to severe…
- Trial name
- QUALITY (NCT01084668)
- Where
- 9 sites in Austria
- Volunteers
- 46 people
- Sponsor
- Abbott
Psoriasis
A Safety and Effectiveness Study of CNTO 1275 in Patients With Moderate to Severe Plaque-type Psoriasis
The purpose of this study is to evaluate the efficacy and safety of initial single and multiple subcutaneous injections of CNTO 1275 in the treatment of patients with moderate to severe plaque psoriasis.
- Trial name
- NCT00320216
- Testing
- Ustekinumab
- Volunteers
- 320 people
- Sponsor
- Centocor, Inc.
Healthy, Plaque Psoriasis
A Study to Investigate the Safety and Tolerability of CAN10 Antibody in Healthy Subjects and in Subjects With Plaque Psoriasis.
This is a first-in-human, randomized, double- blind, placebo-controlled, dose escalation study to investigate how different doses of CAN10 are tolerated, taken up by the body and how long CAN10 stays in the body.
- Trial name
- NCT06143371
- Testing
- CAN10
- Where
- Germany
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.